This is a StreetInsider.com Premium Only Page

Trevena (TRVN) – StreetInsider.com Reports

Apr 17, 2024 11:48 AM Midday movers: Travelers, JB Hunt fall; United Airlines rises

Apr 2, 2024 05:41 AM Trevena (TRVN) PT Lowered to $3 at JMP Securities 'reflecting equity dilution'

Mar 6, 2024 05:04 PM Trevena (TRVN) Receives Nasdaq Delisting Determination, Requested Appeal

Jan 19, 2024 04:36 PM Trevena (TRVN) Announces Share and Warrant Offering by Selling Stockholders

Jan 10, 2024 04:33 PM Trevena (TRVN) Announces Share Offering by Selling Stockholders

Dec 27, 2023 09:11 AM Trevena (TRVN) Announces $4 Million Concurrent Private Placement and Warrant Exercise

Dec 4, 2023 07:04 AM Trevena (TRVN) Awarded OLINVYK Agreement with Premier, Inc.

Nov 30, 2023 07:04 AM Trevena (TRVN) Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

Nov 9, 2023 05:28 PM Trevena (TRVN) Announces Resignation of Board Chair Leon Moulder

Oct 2, 2023 07:01 AM Trevena (TRVN) Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation

Sep 6, 2023 07:03 AM Trevena (TRVN) Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies

Sep 6, 2023 07:01 AM Trevena (TRVN) Receives $15M Non-Dilutive Tranche; Provides General Business Update

Aug 14, 2023 12:56 PM Trevena (TRVN) Reports Q4 Loss of $0.69

Jul 20, 2023 07:02 AM Trevena (TRVN) Appoints Mark Corrigan to its Board

Jun 26, 2023 07:09 AM Trevena (TRVN) Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

May 31, 2023 07:19 AM Trevena (TRVN) Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

May 30, 2023 07:09 AM Trevena (TRVN) Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

May 15, 2023 07:08 AM Trevena (TRVN) Tops Q1 EPS by 107c

May 8, 2023 09:54 AM Trevena (TRVN) Halted Again on Volatility, Up 127%

May 8, 2023 07:04 AM Trevena (TRVN) Announces Approval of OLINVYK in China

Mar 30, 2023 07:05 AM Trevena (TRVN) Reports Q4, Provides Business Update

Mar 30, 2023 07:02 AM Trevena (TRVN) Reports Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

Feb 14, 2023 08:03 AM Trevena (TRVN) Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

Jan 4, 2023 01:06 PM Trevena (TRVN) received a Notice of Allowance for its US patent related to pain treatment

Nov 29, 2022 07:04 AM Trevena (TRVN) Regains Compliance with Nasdaq Listing Requirements

Nov 16, 2022 08:00 AM Trevena (TRVN) Prices 2.64M Share Direct Offering at $3.06/sh

Nov 9, 2022 04:29 PM Trevena (TRVN) Announces 1-for-25 Reverse Stock Split

Nov 9, 2022 07:05 AM Trevena (TRVN) Tops Q3 EPS by 1c

Aug 11, 2022 07:24 AM Trevena (TRVN) Tops Q2 EPS by 1c

Jul 29, 2022 08:01 AM Trevena (TRVN) Announces Proposed Preferred Stock Offering

Jul 28, 2022 07:01 AM Trevena (TRVN) Announces Positive Topline OLINVYK Cognitive Function Data

Apr 20, 2022 07:01 AM Trevena (TRVN) Reports Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK and IV Morphine in Elderly/Overweight Subjects

Apr 18, 2022 07:03 AM Trevena (TRVN) Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

Mar 31, 2022 01:00 PM Trevena (TRVN) PT Lowered to $2 at Cantor Fitzgerald

Mar 31, 2022 07:04 AM Trevena (TRVN) to Receive Up to $40M in OLINVYK ex-US Royalty-Based Financing

Jan 28, 2022 01:49 AM Increasing unusual option volume: SGMS BKLN TIP GNPX FATH TRVN

Jan 27, 2022 09:05 AM Trevena (TRVN) Reports Submission of NDA for OLINVYK by its Partner Jiangsu Nhwa Pharmaceutical in China

Dec 13, 2021 07:08 AM Trevena (TRVN) Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Sep 30, 2021 07:01 AM Trevena (TRVN) Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

Apr 21, 2021 07:07 AM Trevena (TRVN) Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients

Mar 15, 2021 06:23 AM Oppenheimer Starts Trevena (TRVN) at Perform

Feb 10, 2021 06:40 AM Companies with NDRs 2/10

Feb 5, 2021 07:28 AM Companies with NDRs 2/05

Jan 6, 2021 07:03 AM Trevena (TRVN) Reports Update on Commercial Launch Activities for OLINVYK and Announces Anticipated Pipeline Catalysts

Nov 20, 2020 07:07 AM Trevena (TRVN) Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

Oct 30, 2020 07:45 AM Trevena (TRVN) announces oliceridine has been classified as Schedule II controlled substance by the U.S. Drug Enforcement Administration

Sep 14, 2020 06:27 AM Guggenheim Starts Trevena (TRVN) at Buy

Aug 28, 2020 09:19 AM Pre-Open Stock Movers 8/28: (IBIO) (NTNX) (TRVN) Higher; (PLT) (BILL) (OKTA) Lower (more...)

Aug 27, 2020 05:32 PM After-Hours Movers 08/27: (NTNX) (ULTA) (WDAY) Higher; (PLT) (BILL) (OKTA) Lower (more...)

Aug 27, 2020 04:03 PM Cantor Fitzgerald Starts Trevena (TRVN) at Overweight